Clinical trial
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
NCT00416884 · OHSU Knight Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00416884 |
|---|---|
| Title | Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML |
| Official title | Fludarabine, Campath, TBI T-Cell Deplete NMSCT With Post-Transplant T-Cell Infusions for CML Failing Imatinib Therapy With Imatinib (STI571) |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug, Other, Radiation |
| Interventions | Campath, Fludarabine, Total Body Irradiation (TBI), T-Cell Deplete |
| Enrollment | 1 |
| Start date | May 1, 2003 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Dec 28, 2006 |
| Last update posted | Sep 27, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: